-
公开(公告)号:WO2007048557A1
公开(公告)日:2007-05-03
申请号:PCT/EP2006/010194
申请日:2006-10-23
申请人: MEDIVIR AB , SUND, Christian , LINDBORG, Björn , KALAYANOV, Genadiy , SAMUELSSON, Bertil , WALLBERG, Hans , HALLBERG, Anders
发明人: SUND, Christian , LINDBORG, Björn , KALAYANOV, Genadiy , SAMUELSSON, Bertil , WALLBERG, Hans , HALLBERG, Anders
IPC分类号: C07C271/22 , C07C311/06 , C07C275/24 , C07D213/42 , C07D241/12 , C07D333/58 , C07D317/58 , C07D261/08 , A61K31/18 , A61K31/17 , A61K31/325 , A61K31/38 , A61K31/42 , A61K31/44 , A61K31/495
CPC分类号: C07D213/42 , C07C271/22 , C07C275/24 , C07C2602/08 , C07D241/12 , C07D277/24 , C07D333/50
摘要: Compounds of the formula (I), wherein R 1 , R 2 , X and N are as defined in the specification; L is F, NH 2 , NHAlk or N(Alk) 2 n is 1 or 2; A' and A" are terminal groups as defined in the specification. The compounds have utility as HIV-1 protease inhibitors.
摘要翻译: 式(I)的化合物,其中R 1,R 2,X和N如说明书中所定义; L是F,NH 2,NHAlk或N(Alk)2 n是1或2; A'和A“是说明书中定义的末端基团,该化合物可用作HIV-1蛋白酶抑制剂。
-
公开(公告)号:WO2008043704A1
公开(公告)日:2008-04-17
申请号:PCT/EP2007/060557
申请日:2007-10-04
申请人: MEDIVIR AB , JOHANSSON, Nils-Gunnar , KALAYANOV, Genadiy , MARTIN, Joseph Armstrong , SMITH, David Bernard , WINQVIST, Anna
发明人: JOHANSSON, Nils-Gunnar , KALAYANOV, Genadiy , MARTIN, Joseph Armstrong , SMITH, David Bernard , WINQVIST, Anna
IPC分类号: C07H19/073 , A61K31/513 , A61P31/12
CPC分类号: C07H19/073 , A61K31/513 , A61K38/191 , A61K38/193 , A61K38/20 , A61K38/21 , A61K45/06 , A61K2300/00
摘要: 4-Amino-1-((2R,3S,4S,5R)-5-azido-4hydroxy-5-hydroxymethyl-3-methyl-tetrahyclrofuran-2- yl)-1 H-pyrimidin-2-one(22) are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process.
摘要翻译: 4-氨基-1 - ((2R,3S,4S,5R)-5-叠氮基-4-羟基-5-羟甲基-3-甲基 - 四氢呋喃-2-基)-1H-嘧啶-2-酮(22) 丙型肝炎(HCV)聚合酶抑制剂。 还公开了用于抑制HCV和治疗HCV介导的疾病的组合物和方法,用于制备该方法中使用的化合物和合成中间体的方法。
-
公开(公告)号:WO2011070131A1
公开(公告)日:2011-06-16
申请号:PCT/EP2010/069328
申请日:2010-12-10
申请人: TIBOTEC PHARMACEUTICALS , MEDIVIR AB , KALAYANOV, Genadiy , KESTELEYN, Bart, Rudolf, Romanie , PARKES, Kevin , SAMUELSSON, Bengt, Bertil , SCHEPENS, Wim, Bert, Griet , THURING, Johannes, Wilhelmus, J. , WALLBERG, Hans, Kristian , WEGNER, Jörg, Kurt
发明人: KALAYANOV, Genadiy , KESTELEYN, Bart, Rudolf, Romanie , PARKES, Kevin , SAMUELSSON, Bengt, Bertil , SCHEPENS, Wim, Bert, Griet , THURING, Johannes, Wilhelmus, J. , WALLBERG, Hans, Kristian , WEGNER, Jörg, Kurt
IPC分类号: C07D213/64 , C07D213/74 , C07D277/30 , C07D401/12 , C07D405/12 , C07D417/12 , C07D493/04 , A61K31/506 , A61P31/18
CPC分类号: C07D213/64 , C07D213/74 , C07D277/30 , C07D401/12 , C07D405/12 , C07D417/12 , C07D493/04
摘要: HIV inhibitors of formula (I) wherein R 1 is halo, C 1-4 alkoxy, trifluoromethoxy; R 2 is a group of formula (A); R 3 is a group of formula (B); R 4 is a group of formula (C); n is 0 or 1; A is CH or N; R 5 and R 6 are hydrogen, C 1-4 alkyl, halo; R 7 and R 8 are C 1-4 alkyl or C 1-4 alkoxyC 1-4 alkyl; R 9 is C 1-4 alkyl, cyclopropyl, trifluoromethyl, C 1-4 alkoxy, or dimethylamino; R 10 is hydrogen, C 1-4 alkyl, cyclopropyl, trifluoromethyl, C 1-4 alkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.
摘要翻译: 式(I)的HIV抑制剂,其中R 1是卤素,C 1-4烷氧基,三氟甲氧基; R2是式(A)的基团; R3是式(B)的基团; R4是式(C)的基团; n为0或1; A是CH或N; R5和R6是氢,C1-4烷基,卤素; R 7和R 8是C 1-4烷基或C 1-4烷氧基C 1-4烷基; R 9为C 1-4烷基,环丙基,三氟甲基,C 1-4烷氧基或二甲基氨基; R 10是氢,C 1-4烷基,环丙基,三氟甲基,C 1-4烷氧基或二甲基氨基; 其药学上可接受的加成盐和溶剂合物; 含有这些化合物作为活性成分的药物组合物和制备所述化合物的方法
-
公开(公告)号:WO2015034420A1
公开(公告)日:2015-03-12
申请号:PCT/SE2014/051005
申请日:2014-09-02
申请人: MEDIVIR AB
CPC分类号: C07H19/06 , A61K31/7072 , A61K45/06 , C07H19/073 , C07H19/10 , C07H19/11 , C07H19/16 , C07H19/173 , C07H19/20 , C07H19/213 , C07H23/00
摘要: The invention provides compounds of the formula:(I) wherein B is a nucleobase selected from the groups (a) to (d) and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
摘要翻译: 本发明提供式(I)化合物,其中B是选自(a) - (d)组的核碱基,其它变量如权利要求中所定义,其用于治疗或预防丙型肝炎 病毒感染及相关方面。
-
公开(公告)号:WO2015056213A1
公开(公告)日:2015-04-23
申请号:PCT/IB2014/065370
申请日:2014-10-16
申请人: MEDIVIR AB
IPC分类号: C07H19/06 , A61K31/7068 , A61K31/7072 , A61P31/14 , C07H19/10
CPC分类号: A61K31/7072 , A61K31/7068 , A61K45/06 , C07H19/06 , C07H19/10 , C07H19/16
摘要: The invention provides compounds of the formula (I) wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
摘要翻译: 本发明提供式(I)化合物,其中B是选自(a) - (d)组的核碱基,其他变量如权利要求中所定义,其用于治疗或预防丙型肝炎 病毒感染及相关方面。
-
公开(公告)号:WO2012115578A1
公开(公告)日:2012-08-30
申请号:PCT/SE2012/050183
申请日:2012-02-20
申请人: MEDIVIR AB , KALAYANOV, Genadiy
发明人: KALAYANOV, Genadiy
IPC分类号: C07D307/20 , C07H19/173
CPC分类号: C07H1/00 , C07D307/20 , C07H13/08 , C07H15/04
摘要: The present invention concerns the synthesis of substantially anomerically pure 2,3-dideoxy-3- fluoro-5-0-(4-phenylbenzoyl)-a-D-erythropentofuranosyl chloride from an α/β-mixture of the corresponding methyl glycoside. The method of the invention provides the pure a-chloride without the need of anomeric separation. The α-chloride thus achieved is suitable for use as glycosyl donor in the preparation of 2',3'-dideoxy-3'-fluoro nucleosides. In particular, the preparation of 2',3'-dideoxy-3 '-fluoroguanosine, FLG, using an α/β-mixture of the methyl glycoside without the need of anomeric separation is disclosed.
摘要翻译: 本发明涉及从相应的甲基糖苷的α-β混合物合成基本上异头纯的2,3-二脱氧-3-氟-5-0-(4-苯基苯甲酰基)-a-D-赤式呋喃糖基氯。 本发明的方法提供了纯氯化物,而不需要端基分离。 如此实现的a-chloride适合用作制备2',3'-二脱氧-3'-氟核苷的糖基供体。 特别地,公开了使用甲基糖苷的α-β混合物制备2',3'-二脱氧-3'-氟鸟嘌呤,FLG,而不需要异头分离。
-
-
-
-
-